Purpose: To describe changes in HRQoL of pulmonary tuberculosis (PTB)

(Odds ratio, 95 % CI, p = 0.025

In-hospital mortality rates were ϳ6% throughout the study, with the highest rates in adults aged Ն65 years (2009: 8.8%). SP was the most common pathogen reported (1,358/1,544 [88%] isolates). The proportion of 7-valent pneumococcal conjugate vaccine (PCV7) serotypes decreased from 46.7% to 20.1%, while the number and proportion of non-PCV7, 13-valent pneumococcal conjugate vaccine (PCV13) serotype disease increased, led by 19A (nϭ7 [1.3%] to nϭ23 [6.9%]). The most frequently identified serotypes in 2009 were 7F (16.8%), 1 (11.4%), 22F (11.4%), 4 (8.4%), 19A (6.9%), and 3 (6.6%). In children aged 0-4 years, 8, 1, and 0 cases of PCV7 invasive SP pneumonia occurred in 2007, 2008, and 2009, respectively. PCV13 serotypes caused 64.9% of invasive SP pneumonia in 2009, the majority in adults aged Ն60 years. CONCLUSIONS: Although incidence of reportable invasive pneumonia decreased in Norway from 2007-2009, after the pediatric PCV7 National Immunization Program was fully underway, substantial disease burden remains, particularly in older adults. Almost 65% of invasive SP pneumonia cases were caused by pneumococcal conjugate vaccine serotypes.

In-hospital mortality rates were ϳ6% throughout the study, with the highest rates in adults aged Ն65 years (2009: 8.8%). SP was the most common pathogen reported (1,358/1,544 [88%] isolates). The proportion of 7-valent pneumococcal conjugate vaccine (PCV7) serotypes decreased from 46.7% to 20.1%, while the number and proportion of non-PCV7, 13-valent pneumococcal conjugate vaccine (PCV13) serotype disease increased, led by 19A (nϭ7 [1.3%] to nϭ23 [6.9%]). The most frequently identified serotypes in 2009 were 7F (16.8%), 1 (11.4%), 22F (11.4%), 4 (8.4%), 19A (6.9%), and 3 (6.6%). In children aged 0-4 years, 8, 1, and 0 cases of PCV7 invasive SP pneumonia occurred in 2007, 2008, and 2009, respectively. PCV13 serotypes caused 64.9% of invasive SP pneumonia in 2009, the majority in adults aged Ն60 years. CONCLUSIONS: Although incidence of reportable invasive pneumonia decreased in Norway from 2007-2009, after the pediatric PCV7 National Immunization Program was fully underway, substantial disease burden remains, particularly in older adults. Almost 65% of invasive SP pneumonia cases were caused by pneumococcal conjugate vaccine serotypes.